Nectar Lifesciences Limited — Important, 04-08-2025: Updates

Nectar Lifesciences shareholders have approved significant proposals at an Extraordinary General Meeting. Key among these is the transfer of a business to Ceph Lifesciences Private Limited on a 'slump sale' basis, a strategic move impacting company operations. Additionally, shareholders consented to the appointment of Dr. Surulichamy Senthilkumar as a Director, and further, as a Whole-time Director (R&D) for a three-year term. Voting results for these resolutions will be shared separately.